MedTrace Logo

Imipenem Prophylaxis in Patients With Acute Pancreatitis

NCT02897206 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2017-06-20

No results posted yet for this study

Summary

This is a prospective, single-center, randomized, placebo-controlled, double-blind clinical trial that aims to investigate the beneficial and harmful effects of prophylactic use of imipenem in patients with predicted severe acute pancreatitis. All patients with first attack of acute pancreatitis, an onset of disease less than 72h before admission, and an APACHE II score ≥ 8 calculated within the first 24h from admission will be enrolled.

Conditions

Interventions

DRUG

Imipenem

A wide-spectre antibiotic from the carbapenem group

DRUG

Placebo

An imipenem-matching placebo

Sponsors & Collaborators

  • University of Rijeka

    collaborator OTHER

  • University Hospital Rijeka

    lead OTHER

Principal Investigators

  • Davor Stimac, MD, PhD · Department of Gastroenterology, University Hospital Rijeka

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • Croatia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02897206 on ClinicalTrials.gov